Indivior Pharmaceuticals, Inc.

NasdaqGS:INDV Stock Report

Market Cap: US$4.9b

Indivior Pharmaceuticals Management

Management criteria checks 1/4

Indivior Pharmaceuticals' CEO is Joe Ciaffoni, appointed in May 2025, has a tenure of 1.17 years. total yearly compensation is $18.87M, comprised of 3.6% salary and 96.4% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth $28.80M. The average tenure of the management team and the board of directors is 1.2 years and 2.4 years respectively.

Key information

Joe Ciaffoni

Chief executive officer

US$18.9m

Total compensation

CEO salary percentage3.60%
CEO tenure1.2yrs
CEO ownership0.6%
Management average tenure1.2yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Narrative Update • Jul 10

INDV: Turnaround Plan And Index Additions Will Drive Earnings Momentum

Analysts lifted their fair value estimate for Indivior Pharmaceuticals stock from about $37.86 to roughly $50.83, citing expectations for stronger revenue growth, a higher future P/E, and an improved earnings trajectory supported by Indivior's turnaround plan, which is focused on accelerating Sublocade and profitability. What’s in the News for Indivior Pharmaceuticals Indivior Pharmaceuticals was added to the Russell 2000 Defensive, Russell 2000 Growth-Defensive, and Russell 2000 Value-Defensive Indexes on 27 June 2026, broadening its presence across multiple benchmarks and potentially influencing index-tracking fund activity.
Narrative Update • Jun 26

INDV: Raised Guidance And Buybacks Will Support A Turnaround Repricing

Analysts have lifted their price target for Indivior Pharmaceuticals from $50 to about $58, citing expectations for improved revenue growth, a slightly higher discount rate, adjusted profit margins, and a modestly higher future P/E multiple. These expectations are supported by recent research highlighting the company's turnaround plan and its focus on accelerating Sublocade and profitability.
Analysis Article • Jun 18

Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds

Indivior Pharmaceuticals (INDV) is back in focus after fresh attention on its role in treating opioid dependence, prompting investors to reassess the stock’s recent performance and current valuation based on publicly available financial metrics. See our latest analysis for Indivior Pharmaceuticals. The recent focus on Indivior Pharmaceuticals comes against a backdrop of steady gains, with a 30.72% 90 day share price return and a very strong 1 year total shareholder return of 175.54%,...
Seeking Alpha • Jun 09

Indivior: A Stronger Business Than When I First Covered It

Summary Indivior Pharmaceuticals (INDV) is focused on opioid addiction recovery, with SUBLOCADE as its flagship product. Sustained revenue from SUBLOCADE's monthly injection model differentiates INDV from generic addiction treatments. My previous Buy rating was based on the market undervaluing SUBLOCADE's earnings power and operational turnaround potential. The investment thesis has exceeded expectations, validating the strength of INDV's business model and product economics. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Indivior: Trying To Break Addiction

Summary Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery. An analysis around INDV stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 13

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Summary Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x. With new competition from Brixadi, Sublocade maintains 80% market share across new patients. With LAI's low-7% penetration in BMAT, having both options on the market raises awareness for both drugs. The BMAT (Buprenorphine-Medically-Assisted-Treatment) market is expected to grow at a 9.9% CAGR over the next 8 years in the US. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback

Summary Indivior shares sold off on July 9th due to unexpected negative news from management, including the discontinuation of the schizophrenia drug Perseris and lower Sublocade guidance. Below, I argue why the market overreacted to Sublocade's lower FY24 guidance and why I expect Sublocade to continue growing. Current valuation indicates a FY24 EV/EBITDA multiple of sub 5x, offering an attractive entry point if Sublocade sales prove to be robust in the long term. Confidence in Sublocade was signalled by the board's approval of an "accelerated" $100 million repurchase program, which represents 6% of outstanding shares at the current share price of $12.5. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Joe Ciaffoni's remuneration changed compared to Indivior Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$252m

Dec 31 2025US$19mUS$680k

US$210m

Sep 30 2025n/an/a

US$128m

Jun 30 2025n/an/a

US$108m

Mar 31 2025n/an/a

-US$7m

Dec 31 2024US$4kn/a

US$7m

Compensation vs Market: Joe's total compensation ($USD18.87M) is above average for companies of similar size in the US market ($USD8.29M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

CEO

Joe Ciaffoni (55 yo)

1.2yrs
Tenure
US$18,871,196
Compensation

Mr. Joseph J. Ciaffoni, also known as Joe, served as Independent Non-Executive Director at Indivior Pharmaceuticals, Inc. (formerly known as Indivior PLC) since December 17, 2024 until May 2025 and serves...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Ciaffoni
CEO & Director1.2yrsUS$18.87m0.58%
$ 28.8m
Ryan Preblick
Chief Financial Officer6.1yrsUS$3.59m0.20%
$ 10.0m
Christian Heidbreder
Chief Scientific Officer11.6yrsUS$4.18m0.14%
$ 7.1m
Jeffrey Burris
Chief Legal Officer4.6yrsUS$3.52m0.037%
$ 1.8m
Patrick Barry
Chief Commercial Officer1.1yrsUS$5.32mno data
Jason Thompson
Vice President of Investor Relationsno datano datano data
Kevin Espinoza
Chief Integrity & Compliance Officerless than a yearno datano data
Angela Colon-Mahoney
Chief Human Resources Officer1.8yrsno datano data
Vanessa Procter
Executive Vice President of Corporate Affairs1yrno datano data
Alice Givens
Company Secretary1.2yrsno datano data
1.2yrs
Average Tenure
54yo
Average Age

Experienced Management: INDV's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Joseph Ciaffoni
CEO & Director1.2yrsUS$18.87m0.58%
$ 28.8m
Daniel Ninivaggi
Independent Non-Executive Director1.5yrsUS$186.70k0.017%
$ 836.8k
Juliet Thompson
Lead Independent Director5.3yrsUS$251.56k0.010%
$ 495.8k
Stuart Kingsley
Independent Non-Executive Director1yrUS$140.00k0.0046%
$ 226.4k
Barbara Ryan
Independent Non-Executive Director4.1yrsUS$220.47k0.0047%
$ 231.8k
Mark Stejbach
Independent Non-Executive Director5.3yrsUS$217.51k0.017%
$ 833.8k
David Wheadon
Independent Non-Executive Chairman2.1yrsUS$441.03k0.017%
$ 824.9k
Keith Humphreys
Independent Non-Executive Director2.7yrsUS$196.79k0.0078%
$ 386.0k
2.4yrs
Average Tenure
61.5yo
Average Age

Experienced Board: INDV's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/20 11:18
End of Day Share Price 2026/07/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Indivior Pharmaceuticals, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Glen SantangeloBarclays
Graham Glyn ParryBofA Global Research
Chase KnickerbockerCraig-Hallum Capital Group LLC